Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 10/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137126 | 0.94 | AGER (0.41) | AGERC5AR1OPRM1ALDH1A1 | |
| SCHEMBL5135222 | 0.82 | ALDH1A1 (0.46) | AGERGRM7C5AR1OPRM1ALDH1A1 | |
| SCHEMBL5135774 | 0.81 | HSD17B2 (0.40) | AGERC5AR1ALDH1A1 | |
| SCHEMBL5070014 | 0.80 | AGER (0.41) | AGERGRM7C5AR1OPRM1ALDH1A1 | |
| SCHEMBL5134499 | 0.76 | HTR1A (0.40) | AGERC5AR1OPRM1ALDH1A1 | |
| SCHEMBL5135128 | 0.75 | AGER (0.44) | AGERGRM7C5AR1OPRM1ALDH1A1 | |
| SCHEMBL5137387 | 0.75 | MEN1 (0.57) | AGERALDH1A1 | |
| SCHEMBL5136654 | 0.73 | MEN1 (0.49) | ALDH1A1 | |
| SCHEMBL5373300 | 0.73 | MEN1 (0.46) | OPRM1ALDH1A1 | |
| SCHEMBL5136969 | 0.73 | TSHR (0.48) | AGERC5AR1TDP1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |